Panelists discuss how quadruplet therapy has become the new benchmark for NDMM, offering deeper and more durable responses than previous triplet regimens.
Expert Perspectives on Novel Combination Therapy in Newly Diagnosed Myeloma
Panelists discuss how risk stratification using cytogenetic and molecular markers is vital to tailoring NDMM therapy and improving long-term outcomes.
Panelists discuss how comprehensive diagnostic and functional pretesting ensures safe and effective initiation of quadruplet therapy in NDMM.
Panelists discuss how the ADVANCE study was structured to determine whether adding daratumumab to KRd enhances depth and durability of response in NDMM.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
4
What Do Physicians and Patients Think About ADCs as Cancer Treatment?
5
